Anxiety disorders are a group of mental health conditions characterized by excessive, persistent fear, worry, or threat-related hyperarousal that produces functional impairment and may co-occur with panic symptoms, avoidance behaviors, and somatic complaints. Although transient anxiety is common and adaptive, anxiety disorders involve dysregulated threat processing and durable alterations in stress-response circuitry, including cortico-striato-thalamo-cortical loops, the amygdala-centered salience network, and prefrontal control systems. In many patients, symptoms arise from an interaction between genetic vulnerability, early-life experiences, and learned associations that sensitize the individual to perceived danger.
Clinically, anxiety disorders include generalized anxiety disorder (GAD), panic disorder, social anxiety disorder (social phobia), specific phobias, and agoraphobia. GAD is defined by excessive worry occurring more days than not for months, accompanied by difficulty controlling worry and at least several associated symptoms such as restlessness, fatigue, irritability, muscle tension, sleep disturbance, and impaired concentration. Panic disorder involves recurrent unexpected panic attacks—abrupt surges of intense fear or discomfort peaking within minutes—followed by persistent concern about additional attacks or maladaptive behavioral change. Social anxiety centers on fear of negative evaluation in social or performance situations, with avoidance or distress that is disproportionate to actual threat. Phobias typically involve marked fear or anxiety about specific objects or situations, with immediate fear response and avoidance. Agoraphobia refers to fear of situations where escape might be difficult or help unavailable.
Neurobiologically, anxiety disorders have been linked to altered serotonergic and noradrenergic function, increased threat sensitivity, and impaired top-down regulation. Neuroimaging studies often show hyperreactivity in limbic regions during threat tasks and reduced efficiency in cognitive control networks. At the physiological level, dysregulated autonomic arousal—mediated by the hypothalamic-pituitary-adrenal axis and sympathetic pathways—may contribute to symptoms such as palpitations, dyspnea, gastrointestinal distress, tremor, and dizziness. Cognitive mechanisms include intolerance of uncertainty, catastrophic misinterpretation of bodily sensations, attentional bias toward threat cues, and maladaptive safety behaviors that maintain fear through negative reinforcement.
Assessment is primarily clinical and should be structured, longitudinal, and differential. Clinicians evaluate symptom timelines, triggers, avoidance patterns, functional impairment, comorbid depression, substance use, and medical conditions that can mimic anxiety (e.g., hyperthyroidism, arrhythmias, medication effects, stimulant intoxication, caffeine overuse). Standardized instruments such as the GAD-7, PHQ-9 for comorbid depression, and panic- or phobia-specific scales can quantify severity and track response to treatment. Diagnostic formulations should consider whether symptoms are better explained by an anxiety disorder versus trauma-related disorders, obsessive-compulsive and related disorders, bipolar disorder, or psychotic conditions.
Evidence-based treatments are stepwise and often combined. First-line psychotherapy for most anxiety disorders includes cognitive behavioral therapy (CBT), which targets maladaptive thoughts and behaviors. For GAD, CBT incorporates worry scheduling, cognitive restructuring, problem-solving skills, and relaxation strategies. For panic disorder, CBT includes interoceptive exposure (gradual, controlled exposure to feared bodily sensations) and cognitive work addressing catastrophic beliefs. For social anxiety and specific phobias, exposure-based approaches aim to reduce avoidance through graded confrontation with feared stimuli, typically paired with cognitive processing of safety learning. Mindfulness-based and acceptance approaches may be beneficial, particularly for entrenched worry and experiential avoidance.
Pharmacotherapy is indicated when symptoms are severe, chronic, or when psychotherapy is insufficient or inaccessible. Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) are commonly used first-line due to efficacy across several anxiety disorders and favorable long-term tolerability profiles. Dosing often requires gradual titration and adequate duration—clinical improvement may take several weeks. Short-term benzodiazepines can reduce acute symptoms and may be used selectively, but risks include sedation, cognitive impairment, tolerance, dependence, and withdrawal; therefore, they are generally not favored as long-term monotherapy. In treatment-resistant cases, clinicians may consider augmentation strategies, careful evaluation of comorbidities, and referral to specialty care.
A comprehensive management plan includes sleep hygiene, reduction of caffeine and other stimulants, structured activity, and psychoeducation about the role of threat perception and bodily arousal. Relapse prevention should address early warning signs, maintenance exposure or skill practice, and ongoing monitoring of comorbid depression and substance use. Importantly, outcomes improve when treatment targets maintaining mechanisms: avoidance, safety behaviors, attentional bias, and catastrophic interpretation of physiological signals.
Source: [EnergySPG]
S&P Global Energy: Join S&P Global’s Energy CERA Agriculture & Food team for a live mid-year webinar update. – Iran, energy and fertilizers – direct impacts on costs and supply chains – Tariffs after IEEPA – Supply and price outlooks for crops and proteins. #breaking
— @EnergySPG May 1, 2026
SHOP AMAZON BEST SELLERS, CLICK TO BUY FROM AMAZON.
SHOP AMAZON BEST SELLERS, CLICK TO BUY FROM AMAZON.
